// App-Quantinova.ai

e13101 : A phase Ib study of CUDC-101, a multitargeted inhibitor of EGFR, HER2, and HDAC, in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer.

Researchers

Presenter

  • Siqing Fu

Principal Investigators

  • John J. Nemunaitis

  • Alberto Bessudo

  • Julie E. Bauman

  • Omid Hamid

  • Samir E. Witta

  • Grace K. Dy

  • Cheng Lai

  • Robert Laliberte

  • Maurizio Voi

Medical Centers

  • Department of Medical Oncology, The Angeles Clinic and Research Institute, Los Angeles, CA

  • Roswell Park Cancer Institute, Buffalo, NY

  • Mary Crowley Cancer Research Centers, Dallas, TX

  • Pacific Oncology Hematology Associates Inc., Encinitas, CA

  • University of New Mexico, Albuquerque, NM

  • Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, TX

  • Mountain Blue Cancer Care Center, Golden, CO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Liver cancer

  • Lung Cancer

Biomarkers

  • Circulating tumor cells

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Erlotinib hydrochloride

  • CUDC101

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved